Development and validation of UHPLC-MS/MS assay for rapid determination of a carvone Schiff base of isoniazid (CSB-INH) in rat plasma: Application to pharmacokinetic study

Biomedical Chromatography

Volumn 29, Issue 6, 2015, Pages 876-882

  Iqbal, Muzaffar ^a   Bhat, Mashooq A ^a   Shakeel, Faiyaz ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

CSB INH; Pharmacokinetics; Rat plasma; UHPLC MS MS

Indexed keywords

BODY FLUIDS; ELECTROSPRAY IONIZATION; HYDRAZINE; MONOTERPENES; PHARMACOKINETICS; RATS;

CARBAMAZEPINE; CARVONE; CSB-INH; INTERNAL STANDARDS; PHARMACOKINETIC STUDIES; RAT PLASMA; SCHIFF-BASE; SINGLE-STEP; U-HPLC-MS; UHPLC-MS/MS;

ACETONITRILE;

ACETONITRILE; AMMONIUM ACETATE; CARBAMAZEPINE; CARVONE; CARVONE SCHIFF BASE OF ISONIAZID; ISONIAZID DERIVATIVE; SCHIFF BASE; UNCLASSIFIED DRUG; ISONIAZID; TERPENE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; EUROPEAN MEDICINES AGENCY; FLOW RATE; FOOD AND DRUG ADMINISTRATION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPH; MALE; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; MONITORING; NANOEMULSION; NONHUMAN; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; RAT; SUSPENSION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY; ANIMAL; BLOOD; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; WISTAR RAT;

RATTUS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ISONIAZID; LIMIT OF DETECTION; LINEAR MODELS; MALE; MONOTERPENES; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SCHIFF BASES; TANDEM MASS SPECTROMETRY;

EID: 84929403810     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3368     Document Type: Article

References (11)

1. Bhat MA and Al-Omar MA. Synthesis, characterization, and in vitro anti-Mycobacterium tuberculosis activity of terpene Schiff bases. Medicinal Chemical Research 2013; 22: 4522-4528.
2. European Medicines Agency. Guideline on Bioanalytical Method Validation, 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (accessed on 22 February 2014).
3. US Food and Drug Administration. Guidance for Industry on Bioanalytical Method Validation, 2001. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (accessed on 22 February 2014).
4. Iqbal M, Ezzeldin E, Al-Rashood KA, Al-Khamees KI, Khan RM, Raish M and Anwer T. Simple and rapid determination of zafirlukast in plasma by ultra-performance liquid chromatography tandem mass spectrometric method: application into pharmacokinetic study in rabbits. Drug Research (Stuttgart) 2013; 64: 412-419.
5. Kumar A, Saini G, Nair A and Sharma R. UPLC: a preeminent technique in pharmaceutical analysis. Acta Poly Pharmacy 2012; 69(3): 371-380.
6. Kumar HSN, Parumasivam T, Jumaat F, Ibrahim P, Asmawi MZ and Sadikun A. Synthesis and evaluation of isonicotinoyl hydrazone derivatives as antimycobacterial and anticancer agents. Medicinal Chemical Research 2014; 23: 269-279.
7. Li F, Maguigad J, Pelzer M, Jiang X and Ji QC. A novel 'peak parking' strategy for ultra performance liquid chromatography/tandem mass spectrometric detection for enhanced performance of bioanalytical assays. Rapid Communication in Mass Spectrometry 2008; 22(4): 486-494.
8. Liu G, Snapp HM, Ji QC and Arnold ME. Strategy of accelerated method development for high-throughput bioanalytical assays using ultra high-performance liquid chromatography coupled with mass spectrometry. Analytical Chemistry 2009; 81: 9225-9232.
9. Nováková L, Matysová L and Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006; 68(3): 908-918.
10. Singh M, Sasi P, Rai G, Gupta VH, Amarapurkar D and Wangikar PP. Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line. Medicinal Chemical Research 2011; 20: 1611-1615.
11. Zheng N, Zeng J, Akinsanya B, Buzescu A, Xia YQ, Ly V, Trouba K, Peng Q, Aubry AF and Arnold ME. A rapid, accurate and robust UHPLC-MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies. Journal of Pharmaceutical and Biomedical Analysis 2013; 83:237-248.